Patient and Public Involvement and Engagement (PPIE)
As part of the PHOENIX trial, we are committed to shaping our research and dissemination with our Patient and Public Involvement and Engagement (PPIE) group.
The PHOENIX Trial Design PPIE Meetings
Over the 26th and 27th of March 2024, 16 participants attended the PHOENIX PPIE meetings to discuss our proposed trial.
The PPIE group included individuals with either prior personal/shared experience of adverse drug reactions, recent hospital admissions or encounters with specialty outpatients for medication changes and/or individuals on more than 5 medications.
At these events, the PHOENIX clinical research team explained the trial design by providing patient-facing documents and a short presentation to facilitate interactive discussion.
The team compiled all key feedback into a PPIE report, and this information was used to refine our trial design to reflect the advice of the PPIE group.
PPIE Organisational Team (Left to Right): Ms Emma Johnston, Dr Louise Bennett, Dr Linsay McCallum, Professor Sandosh Padmanabhan, Dr Stefanie Lip, Dr Iain Frater and Ms Lauren Blackman
PPIE Group Feedback
The PPIE group unanimously agreed that the timing of the PHOENIX trial is opportune, and that pharmacogenomics (PGx) testing is relevant and brings potential benefits for NHS patient care.
Areas where comments were taken on board in the updated trial design include:
- Patient Information Sheet and Data Privacy
- Screening, Identification and Consent
- Results of the PGx Test
- Questionnaires for Quality of Life
- Trial Benefits
- Wider use of PGx testing
- Future Planning Considerations
- PGx Education
Acknowledgements
We extend our heartfelt gratitude to all the participants who joined us for the PPIE group meetings, as their active involvement has been instrumental in laying the groundwork for the successful preparation of the PHOENIX trial.
Without their valuable contributions and commitment, this endeavour would not have been achievable.